Novartis AG (BCBA:NVS)
Argentina · Delayed Price · Currency is ARS | Market Cap | 466.36T +40.2% |
| Revenue (ttm) | 83.99T +2.7% |
| Net Income | 18.90T -6.6% |
| EPS | 9,799.73 -3.4% |
| Shares Out | n/a |
| PE Ratio | 24.68 |
| Forward PE | 17.62 |
| Dividend | 988.41 (1.53%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 6 |
| Open | 64,375 |
| Previous Close | 64,600 |
| Day's Range | 64,375 - 64,775 |
| 52-Week Range | 42,140 - 67,200 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 27, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USD Financial StatementsNews
Drugmakers quietly halted autoimmune drug trials because of deaths or problematic side effects, raising questions about disclosure around experimental research
Trial freezes by Novartis and Bristol Myers have triggered a race to understand why a promising autoimmune treatment turned risky.
Novartis Rises as $3.22 Billion Deal Targets Faster Drug Delivery
Novartis Rises as $3.22 Billion Deal Targets Faster Drug Delivery
Novartis Signs Up To $3.2B Hybrozyme Deal With Alteogen
(RTTNews) - Alteogen Inc. (196170.KQ), a South Korea-based biopharmaceutical company specializing in platform technologies, announced it has entered into an option and license agreement with Novartis ...
Novartis could cut about 130 jobs in Basel site relocation
Novartis could cut about 130 jobs in Switzerland as it relocates laboratory activities and shuts down some production in Basel, the Swiss drugmaker said on Wednesday.
Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology
South Korea's Alteogen said on Wednesday it has signed a deal with Novartis worth up to $3.22 billion, giving the Swiss drugmaker access to its technology to make injectable versions of intravenous dr...
A Look at Novartis AG (NVS) After 6.0% Gain -- GF Value $130.84 vs Price $161.25
A Look at Novartis AG (NVS) After 6.0% Gain -- GF Value $130.84 vs Price $161.25
Novartis Jumps 6% as MS Drug Meets Goals in Two Phase 3 Trials
Novartis Jumps 6% as MS Drug Meets Goals in Two Phase 3 Trials
H.C. Wainwright says Novartis success in RMS trials does not impact TG’s Briumvi
After Novartis (NVS) announced topline data from the REMODEL-1/-2 trials of remibrutinib in relapsing multiple sclerosis, H.C. Wainwright analyst Emily Bodnar believes that remibrutinib will be favore...
Novartis Reported Encouraging Trial Data for a Multiple Sclerosis Drug. The Stock Is Jumping
Promising results from a recent clinical trial are boosting Novartis shares this morning.
Novartis Stock (NVS) Pops as Multiple Sclerosis Drug Shows Positive Results in Late-Stage Trials
Novartis ($NVS) stock rose about 6% at the time of writing on Tuesday, after the Swiss drugmaker reported positive results from two late-stage trials of remibrutinib in relapsing multiple sclerosis.
Novartis Halts Eight Trials After Three Patient Deaths
Novartis Halts Eight Trials After Three Patient Deaths
Why Novartis Just Surged 6%, Eyeing A Breakout
Novartis stock surged early Tuesday after its experimental multiple sclerosis treatment succeeded in a pair of midstage studies.
Why Novartis Stock Is Heading for Its Best Day Since 2023 After 3 Patient Deaths
Novartis says it has paused clinical trials for rap-cel in patients with autoimmune disease, while reporting positive data for a different potential blockbuster.
Novartis' Phase 3 REMODEL Trials For Remibrutinib In Multiple Sclerosis Meet Primary Endpoint
(RTTNews) - Novartis AG (NVS), a pharmaceutical company, released on Tuesday positive topline results from the Phase 3 REMODEL-1 and REMODEL-2 trials for remibrutinib in adults with relapsing multiple...
Sandisk, Marvell, Robinhood, Novartis, Dell, and More Stocks That Explain Today's Market
AI stocks including Sandisk, Corning, and Intel struggle as investors ditch risk assets amid a run-up in bond yields.
Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
Novartis shares rose after the drugmaker reported positive results in two late-stage trials from its new pill for the most common form of multiple sclerosis.
Novartis announces results from Phase III Remodel-1/-2 trials of remibrutinib
Novartis (NVS) announced positive topline results from its Phase III Remodel-1/-2 trials of remibrutinib in relapsing multiple sclerosis. Remibrutinib, a highly selective and potent oral Bruton’s tyro...
Novartis halts autoimmune CAR-T trials following three deaths, Reuters says
Novartis (NVS) has paused eight clinical trials of rap-cel, an experimental cell therapy targeting autoimmune and neurological disorders, after three patients died, Reuters’ Shivani Tanna and Bhanvi S...
Novartis Halts Trials For Rap-cel Immunotherapy Following Deaths From Severe Immune Reaction
(RTTNews) - Novartis AG (NOVN.S), a pharmaceutical company, has reportedly paused eight clinical trials evaluating rap-cel, a CD19 CAR-T cell therapy, following the deaths of three patients enrolled i...
Stocks making the biggest moves premarket: Nvidia, Robinhood, Novartis & more
These are the stocks posting the largest moves premarket.
Novartis' oral multiple sclerosis drug meets main goal in late stage studies
Swiss drugmaker Novartis said on Tuesday that its oral drug, remibrutinib, met the main goals in two late-stage studies, showing superiority over a rival drug in reducing relapse rates in patie...
Novartis (NOVN) Halts Clinical Trials Following Patient Deaths
Novartis (NOVN) Halts Clinical Trials Following Patient Deaths
Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports
Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late August, after three patients died, the Wall Street Journal reported on Tuesda...
Novartis Pauses Autoimmune Cell Therapy Studies After Deaths
Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late August, after three patients died.
AstraZeneca's blocked M&A signals tough CEO finale
The former sector leader trades at a discount to Novartis and Roche, amid growth fears. Pascal Soriot, whose 14-year tenure already counts one turnaround, ran into opposition to a union with $137 bln ...